This page contains a Flash digital edition of a book.
28 2011


IMAGING & ONCOLOGY


REFERENCES 1. Leksell L. The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951; 102:316-319.


2. Martin A, Gaya A. Stereotactic body radiotherapy: A review. J Clin Oncol; 2010; 22: 157-172.


3. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora s, Francescon P. Cyberknife radiosurgery for benign meningiomas: short term results in 199 patients. Neurosurgery; 2009;64:A7-13.


4. Soltys S G, Adler J R, Lipani J D, Jackson P S, Choi C Y, Puataweepong P, White S, Gibbs I C, Chang S D. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys; 2008; 70:187-193.


5. Roh K W, Jang J S, Kim M S, Sun D I, Kim B S, Jung S L, Kang J H, Yoo E J, Yoon S C, Jang H S, Chung S M, Kim Y S. Fractionated stereotactic radiotherapy as reirradiation for local recurrent head and neck cancer. Int J Radiat Oncol Biol Phys; 2009; 74:1348-1355.


6. Rwigema J C, Heron D E, Ferris R L, Gibson M, Quinn A, Yang Y, Ozhasoglu C, Burton S. Fractionated stereotactic body radiation therapy in the treatment of previously- irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol; 2010, 33, 3, 286-293).


7. Gangnon G J, Nasr N M, Liao J J, Milzahn I, Marsh D, McRae D, Henderson F C. Treatment of spinal tumours using Cyberknife fractionated stereotactic radiosurgery: pain and quality of life assessment after treatment in 200 patients. Neurosurgery; 2009; 64:297:306.


8. Gerszten P C, Burton S A, Ozhasoglu C, Welch W C. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine; 2007; 32:193:199.


9. Collins B T, Vahdat S, Erickson K, Collins S P, Suy S, Yu X, Zhang Y, Subramaniam D, Reichner C A, Sarikaya I, Esposito G, Yousefi S, Jamis-Dow C, Banovac F, Anderson E D. Radical cyberknife radiosurgery with tumour tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol; 2009; 2:1.


10. Van der Voort van Zyp N C, Prevost J B,


Hoogeman M S, Praag J, van der Holt B, Levendag P C, van Klaveren R J, Pattynama P, Nuyttens J J. Stereotactic radiotherapy with real-time tumour tracking for non- small cell lung cancer: clinical outcome. Radiother Oncol; 2009; 91:296:300.


11. Stintzing S, Hoffmann R T, Heinemann V, Kufeld M, Muacevic A. Frameless single session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer;2010; 46:1026-1032.


12. King C R, Brooks J D, Gill H, Pawlicki T, Cotrutz C, Presti J C. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys; 2009; 73:1043-1048.


13. Katz A J, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ- confined prostate cancer. BMC Urol; 2010; 10:1.


14. Kilby W, Dooley J R, Kuduvalli G, Sayeh S, Maurer C R. The Cyberknife robotic radiosurgery system in 2010. Technology in cancer research and treatment; 2010; 9:5:433-452.


15. Murphy M J. Fiducial-based targeting accuracy for external beam radiotherapy. Med Phy; 2002; 29:334-344.


16. Kothary N, Heit J J, Louie J D, Kuo W T, Loo B W, Koong A, Chang D T, Hovespian D, Sze D Y, Hofmann L U. Saftey of percutaneous fiducial marker implantation for image- guided radiation therapy. J Vasc Interv Radiol; 2009; 20:235-239.


17. Aoyama H, Shirato H. Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. JAMA; 2006; 295: 2483-2491.


18. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable medically inoperable, early stage (I/II)non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2002; 54:119-130.


19. Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer; 2003; 41:1-11.


20. Wagner T, Yang G. The role of chemotherapy and radiation in the


treatment of locally advanced non- small cell lung cancer (NSCLC). Curr Drug Targets; 2010; 11:1:67-73.


21. Onishi H, Shirato H, Nagata Y , Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyma M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol; 2007; 2: S94-100.


22. Timmerman R D, Park C, Kavanagh B D. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol; 2007; 2:s101-112.


23. Chang J Y, Roth J A. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin; 2007; 17:251-259.


24. Willner J, Baiee K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumour control predictions in primary radiotherapy of non small cell lung cancer. Int J Radiat Oncol Biol Phys; 2002; 52:382-389.


25. Seppenwoolde Y, Berbeco R I, Nishioka S, Shirato H, Heijmen B. Accuracy of tumour motion compensation algorithm from a robotic respiratory tracking system: a simulation study. Med Phy; 2007; 34:2774:2784.


26. Kavanaugh B D, Timmerman R D. Editors. Stereotactic body radiation therapy; 2005;Philadelphia, PA:Lippincott.


27. Hurkmans C W, Cuijpers J P, Lagerwaard F J, Widder J, van de Heide U A, Schuring D, Senan S. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working party of the randomised phase III ROSEL study. Radiat Oncol; 2009; 4:1.


28. Brown W T, Wu X, Fayad F, Fowler J F, Amendola B E, García S, Han H;, de la Zerda A, Bossart E, Huang Z, Schwade J G. Cyberknife radiosurgery for stage I lung cancer: Results at 36 months. Clinical lung cancer; 2007; 8:8.


29. Mulier S, Ruers T, Jamart J, Michel L, Marchal G, Ni Y. Radiofrequency ablation versus


resection for resectable colorectal liver metastases: time for a randomized trial? An update. Dig Surg; 2008; 25(6):445-460.


30. Vargas C, Martinez A, Boike T, Spencer W, Goldstein N, Gustafson G, Krauss D, Gonzalez J. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a Phase I to II study. Int J Radiat Oncol Biol Phys 2006;66:416–423.


31. Fowler J F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol; 2005; 44:265-276.


32. Morgia G, De Renzis C. Cyberknife in the treatment of prostate cancer: A revolutionary system. European Urology; 2009; 56:40-42.


33. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, Johansson KA, Ekberg L, Morhed E, Paludan M, Wittgren L, Blomgren H, Lewensohn R. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol; 2006;45(7):787-95.


34. Lagerwaard F, Haasbeek C, Smit E, Slotman B, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2008; 1;70(3):685-92.


35. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys; 2005; 63(5):1427-31.


36. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DeRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol; 2006; 24:4833-4839.


37. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small- cell lung cancer. Int J Radiat Oncol Biol Phys; 2006; 66(1):117-25.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72